Literature DB >> 3887670

Assessment of cyclosporin A in whole blood and plasma in five patients with different hematocrits.

R P Agarwal, R A McPherson, G A Threatte.   

Abstract

Measurement of whole blood and plasma levels of cyclosporin A (CsA) by radioimmunoassay in kidney transplant recipients receiving the drug showed that CsA concentrations in plasma increased nonlinearly when whole blood levels of the drug exceeded 1,000 ng/ml. At low plasma levels (less than 200 ng/ml), most of the CsA in the blood was in the nonplasma component, indicating that cellular elements have high affinity for CsA. Comparison of nonplasma CsA concentrations in two patients with hematocrit values of 32.5 and 35% showed that in the patient with a hematocrit of 35% the cellular associated drug was twice as great as that in the other patient, indicating that there may be significant differences in the cellular affinity of CsA in patients with similar hematocrits. Linear regression analysis of the cellular associated CsA versus plasma levels of the drug in a double-reciprocal plot showed a drug saturation capacity of 6,060 ng/ml in the nonplasma component of blood in the patient with a hematocrit of 35%. Similar analyses in the other patients indicated saturation capacities ranging from 4,750 to 10,400 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3887670     DOI: 10.1097/00007691-198503000-00010

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations.

Authors:  J Grevel; K L Napoli; M S Welsh; N E Atkinson; B D Kahan
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

2.  The influence of haematocrit on blood cyclosporin measurements in vivo.

Authors:  A Johnston; J T Marsden; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

3.  Assessment of variables contributing to cyclosporine distribution in blood.

Authors:  S O Broin; E Clarke; S McCann
Journal:  Ir J Med Sci       Date:  1990 Sep-Dec       Impact factor: 1.568

Review 4.  Therapeutic monitoring of cyclosporin--an update.

Authors:  A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

Review 6.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

Review 7.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.